MENU
AUG 30, 2016 8:00 AM PDT

Precise generation of desired human cell-types from embryonic stem cells

Speaker
  • Senior Research Fellow, Genome Institute of Singapore, Singapore
    Biography
      Lay Teng Ang is currently a Visiting Assistant Professor at Stanford University and a Senior Research Fellow at the Genome Institute of Singapore, A*STAR. She received her B.A. (Honours) in Bioengineering from the National University of Singapore and her Ph.D. from the University of Cambridge under an A*STAR Scholarship. Lay Teng has eleven years of research experience and dedicated the past nine years working with human embryonic stem cells (hESCs) and their differentiation towards endodermal and mesodermal cells. Her research has been supported by two ETPL Gap Funding Grants from A*STAR (as PI and co-PI, respectively) and has led to manuscripts in Cell and Cell Stem Cell (as corresponding author). She further led the commercialization effort to position her technology as a research kit, which is now sold worldwide by Thermo Fisher Scientific, Inc. Her ultimate goal is to develop new human cell types for use in regenerative medicine and drug toxicology testing.

    Abstract

    My research program focuses on building the technology to generate diverse human cell-types for application in regenerative medicine and drug toxicology testing. While embryonic stem cells (ESCs) have the potential to generate thousands of distinct human cell-types, this vast array of lineage choices has made it difficult to efficiently differentiate ESCs towards any single desired fate. To more accurately guide ESC differentiation, we have delineated comprehensive roadmaps that describe how ESCs are diversified into a wide variety of endodermal and mesodermal cell-types. These roadmaps have enabled the successful generation of human liver cells and bone progenitors that can engraft in mouse models and respectively regenerate human liver tissue or bones in vivo; as such these ESC-derived tissue progenitors serve as potential sources of human cells for regenerative medicine or drug toxicology testing
     


    Show Resources
    You May Also Like
    JUN 23, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 23, 2020 10:00 AM PDT
    DATE: June 23, 2020 TIME: 10:00am PT Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, s...
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    AUG 18, 2020 10:00 AM PDT
    C.E. CREDITS
    AUG 18, 2020 10:00 AM PDT
    DATE: August 18, 2020 TIME: 10:00am PT Get deeper understanding of gene expression patterns by using assays that retain spatial organization at single cell resolution! Come learn about the n...
    JUN 09, 2020 3:00 PM CEST
    C.E. CREDITS
    JUN 09, 2020 3:00 PM CEST
    DATE: June 9, 2020 TIME: 6am PT, 9am ET, 3pm CEST The importance of disposable plastic consumables and their overall impact on the experimental workflow of qPCR has been taken into considera...
    JUL 30, 2020 10:00 AM PDT
    C.E. CREDITS
    JUL 30, 2020 10:00 AM PDT
    DATE: July 30, 2020 TIME: 10:00am PT Regenerative medicine has become a key focus worldwide and the number of stem cell, especially pluripotent stem cell (PSC)-based clinical trials are rapi...
    Loading Comments...
    Show Resources
    Attendees
    • See more